Article Details
Retrieved on: 2022-11-10 08:11:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology ...
Article found on: www.wdrb.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here